Valeant ups offer for Salix, Endo throws in the towel
This article was originally published in Scrip
Executive Summary
Valeant Pharmaceuticals has agreed an increased all-cash offer price for Salix Pharmaceuticals of $173 per share, up from its earlier $158 offer, prompting Endo International to pull out of the bidding war for the gastro-intestinal products specialist.